www.mydario.com
OTCQB: DRIO This presentation of LabStyle Innovations Corp. (the “ Company ” ) and statements of the Company ’ s management or agents related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate“, ‘will”, “would” and other similar expressions all denote forward-looking statements within the meaning of the Act. Factors that could cause or contribute to such differences include the Company ’ s compliance with regulatory requirements, the Company ’ s status as a new public company, the impact of current and any future competition, as well as other factors and risks discussed in the Company's filings (including the results of the company’s commercial and regulatory plans for Dario™) with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. In addition, readers are cautioned that any estimates, forecasts or projections contained in this presentation or as may be discussed by Company management or its agents have been prepared by Company management in good faith on a basis believed to be reasonable. However, such estimates, forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to the future performance of the Company. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in conformance with generally accepted accounting principles. www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO Reimbursement received USA Costa Rica Panama Canada Italy Australia Soft Launch (UK/NZ) Netherland Q3/14 Q4/14 Q1/15 Q2/15 Q3/15 www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO Glucose Monitoring, $12bn Therapy - Insulin, $54bn (Source: International Diabetes Federation) www.mydario.com
OTCQB: DRIO 24/7 Behavioral Change Support Tool/Medicine www.mydario.com
OTCQB: DRIO Dario Mobile Management Platform Dario 24/7 Support Dario Mobile Solution Social Network Clinical Program Library Daily feedback to adjust and optimize treatment www.mydario.com
OTCQB: DRIO Personalized Treatment Overall Diabetes Management Decision support www.mydario.com
OTCQB: DRIO Lancing device Smart Meter plugs into smart mobile devices (one device iOS + Android) 25 Strip Cartridge – GOD technology Compact Tin le Highl Co Tiny bl bloo ood sam ample Highly acc accurate oid Ine ive High iOS/ OS/Androi nexpensiv ghly ly usab usable le - No No ba battery ry 2013 Pot CE CE Mar Mark gr granted in n Sep September 2013 otentia ial l 2015 2015 FD FDA A app approval l www.mydario.com
OTCQB: DRIO Patient Supporters • Easier monitoring • Remote support • Auto alerts Payers • Online patient monitoring • Improve compliance • Reduce healthcare costs www.mydario.com
OTCQB: DRIO Basic Feature BGM for All-in one Smartphone BGM Insulin Cellular (Roche Connected (Freestyle, Users connectivity Company Accu- (iBGStar, Verio, (Aviva (Liveongo, Chek iHealth Contour, Expert, Telcare) Mobile) Align, 2in1) Aviva etc.) Insulinx) All-in-one Kit Device Pocket sized Powerless / iOS/Android Information sharing with doctors and relatives Disease Management / / Actionable insights Insulin recommendation Estimated HBA1C Community platform / Mentor platform / Clinical Programs Pricing www.mydario.com
OTCQB: DRIO Smartphone Compatible iOS/android compatibility limitations Hardware Dedicated Device Logger Software Disease management www.mydario.com
OTCQB: DRIO • 85% reimbursement & out of pocket • Disposable strips (recurring revenue model) • Service fees for behavioral programs improving clinical outcome • Meta analysis for Payers and HMO’s • Insurers online monitoring • Clinical studies platform • Tele-care providers www.mydario.com
OTCQB: DRIO $600 $500 $400 Data Monitization $300 Behavioral programs Monitoring $200 $100 $0 0.1% 0.2% 0.5% 1.0% 2.0% www.mydario.com
OTCQB: DRIO Prescription / Reimbursement B2B B2C Labstyle Innovations - Distributors sales force to Direct online marketing, drive sales through email, App, Facebook, SEO healthcare professionals (GP’s) www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO www.mydario.com
OTCQB: DRIO Name Experience Headquarters Erez Raphael • 20 years of experience in building product organizations – from Design to Acting Chairman and commercialization. Israel • Formerly with Amdocs (NYSE: DOX) and Nokia-Siemens. CEO • Zvi Ben-David 25 years of experience with public and private medical device companies • CFO of Given Imaging Ltd. (formerly Nasdaq: GIVN), and UltraShape Medical Israel CFO Ltd. • 25 years of experience in the medical device industry. Bill McGrill, RAC • Experienced in new product development and regulatory affairs for clearance U.S. VP Regulatory of medical products in the U.S., European Union, Canada and a number of other foreign markets • David Edelman Entrepreneur and patient advocate who has dedicated his career to using technology to improve health and happiness. Director Product U.S. • President of Diabetes Daily, a leading online community and educational Strategy platform. • 16 years of executive leadership in the Medical Device Industry. Eran Kurma n • Israel Extensive experience in global strategic marketing, business development, VP, Global Strategy and clinical development knowledge. Dror Bacher • 15 years of software business experience Israel • Managing product development at mobile and semi-conductor companies. VP R&D www.mydario.com
OTCQB: DRIO Name Experience • Head of Diabetes Unit and Research Center, Hadassah Medical Center Prof Itamar Raz, MD • Israel National Council of Diabetes of the Israel Ministry of Health Head of SAB • President, Israel Diabetes Research Group. • Type 1 diabetes since 1985 acknowledged as the 2014 Diabetes Educator of the Year by the American Association of Diabetes Educators. Gary Scheiner, CDE MS • Known for his globally-available coaching services at IntegratedDiabetes.com. • An internationally recognized expert in the behavioral aspects of diabetes management. Dr. William Polonsky, PhD • Co-founded the Behavioral Diabetes Institute Author of numerous books on Diabetes. • Dietitian and diabetes educator for nearly thirty-five years. Hope Warshaw, MMSc • Owner of consulting practice, for corporate consulting to consumer and professional writing and RD CDE BC-ADM individual diabetes and weight management counseling. • Former Senior Medical Advisor at Eli Lilly, held teaching positions at Ohio University and Dr. Paul Rosman Northeastern Ohio Universities College of Medicine • Former President or Chair of American Diabetes Association, American Association of Clinical DO FACP FACE FACOI Endocrinologists, and the Ohio Diabetes Prevention and Control Program • Professor of Endocrinology and Metabolic Diseases, • Head of Department at the University Campus Bio-Medico in Rome, Italy Dr. Paolo Pozzilli, MD • Professor of Diabetes Research at St. Bartholomew’s and the London School of Medicine. • Professor of Medicine, Endocrinologist and Angiologist at the Munich Diabetes Research Group in Dr. Eberhard Standl,MD Germany. Has developed his career in both Munich, and at the Joslin Diabetes Center in Boston. www.mydario.com
OTCQB: DRIO www.mydario.com
Recommend
More recommend
